Drugs / QLC5508
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07620041 | Jun → Dec 2026 expected | neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07198633 | Nov 2025 → Dec 2026 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07256782 | Oct 2025 → Oct 2026 expected | neoplastic disease or syndrome | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07802821 | Oct 2026 → Mar 2029 expected | small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07632690 | Jun 2026 → Jun 2028 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07463573 | Apr 2026 → Jun 2028 expected | esophageal squamous cell carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-08-25 | Qilu Pharmaceutical Co., Ltd. | Results 金融界丨齐鲁制药ADC创新药QLC5508临床研究成果入选2025年世界肺癌大会口头报告 qilu-pharma.com ↗
综上所述，QLC5508 在既往经治的 ES-SCLC 患者中显示出了显示出了优越的安全性、突出的抗肿瘤活性和长期的生存获益，2.0 mg/kg Q2W将作为后续进一步研究的推荐剂量。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-08-25 | Qilu Pharmaceutical Co., Ltd. | 金融界丨齐鲁制药ADC创新药QLC5508临床研究成果入选2025年世界肺癌大会口头报告 qilu-pharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLC5508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07620041 ↗ |
| Modality | Other / unclassified | “B7H3 ADC” NCT07198633 ↗ |
| Route | Other | “QLC5508 will be administered by injection” NCT07198633 ↗ |